Fe'au'auhi ki ha Huhu malu‘i COVID-19 pea kuo 'asi mai 'a e ola Featured
London & New York: Ko e fe‘au‘auhi ‘a e ngaahi kautaha hu‘ivai-faito‘o lalahí ke ma‘u ha huhu-malu‘i, pe huhu-ta‘ofí (vaccine) ‘o e Covid-19 kuo takimu‘a mai ai ‘a e Pfizer, Inc., kautaha hu‘ivai faito‘o ‘Amelika mo honau kaungā-pisinisi Siamané ko e BioNTech. Ko ‘enau faito‘ó fo‘oú ni (BNT162b2) kuo huhu sivi‘i ‘i he kakai ‘e toko 43,000 pea kuo ola lelei ai ‘a e 90% mei he Covid-19.
Na‘e tukumai ‘a e ongoongó ni ‘e he ongo kautahá ‘i he Mōnite, Nov. 9, 2020. ‘Oku fakaofo ‘a e ola lelei ‘a hono sivi ‘o e BNT162b2 ko ‘ene lakasi ‘a e leleitahá ‘o ha faito‘o huhu-malu‘i fo‘oú ‘o e lolotongá ní ko e 70%. Lau ia ‘a e makasini ko ‘ení, “The Economist.”
‘Oku ‘iloa foki mo e ongo faito‘o huhu ‘a e kautaha hu‘ivai Pilitānia ko e AstraZeneca, ‘oku ‘i ai mo honau va‘a fekumi faito‘o ‘i he Oxford University. Pea kauatu ki ai mo e kautaha ‘Ameliká ko e Moderna. Ka ko e founga hokomai ki he BNT162b2 ‘a e Pfizer mo e BioNTech ko ‘ena ma‘u ngofua faka-lao ki hono tufaki ‘o e faito‘ó ni ‘i ‘Ameliká mo ‘Iulopé. Kuo pau ke laiseni ‘e he fonua takitaha, tukukehe ‘a e ngaahi fonua iiki ‘oku nau falala ki he WHO ‘o e United Nations.
Laisení mo hono tufakí ‘i māmani kotoá
Ko e laiseni ngofua ke tufaki ‘a e faito‘o huhu BNT162b2 ‘a e Pfizer & BioNTech ‘e toki avamai kenau tohi kole ki ai ‘i he uike 3 ‘o Nōvemá, 2020. Kuo pau kenau tānaki mai ‘a e ngaahi fakamo‘oni malu‘i (safety data) mei he kakai na‘á nau siví fe‘unga mo e māhina ‘e 2.
‘Oku fakafuofua ‘a e “The Economist” ‘e ‘uluaki fakangofua mai ‘a hono tufaki ‘o e faito‘o huhú BNT162b2 ki he kau toketā mo e kau neesí ‘oku nau tu‘u mu‘omu‘á ‘i he laine tau‘i ‘o e Covid-19. ‘Oku mahu‘inga kenau lava ‘o fai ‘enau ngāué fiemālie mo ‘ikai kenau manavahē ki he mahakí. Pea ‘e toki hoko mai hono tufaki ki he kāifonuá (public) ‘i he kuata ‘uluaki ‘o e 2021.
Na‘e talu foki e kamata hono ngaohi ‘o e BNT162b2 ‘i he māhina kuo ‘osí (‘Okatopa) ke ma‘u ai e fakafuofuo ki he vahe-faito‘o (medicinal dose) ‘e 50 miliona ke ngāue ‘aki ‘i he toenga ‘o e 2020. Pea ‘e hiki haki ai ki he 1.3 piliona ‘i he 2021, ko e fakafuofua ia ‘a e Pfizer & BioNTech.
Ka ko e fiema‘ú ia ki māmani kotoá ‘e fu‘u lahi ‘aupito ia ke faka-kakato tokotaha ‘e he BNT162B2, lau ia ‘a e CEO Richard Hatchett ‘o e kautaha NGO ko e CEPI. ‘Okú ne poupou ki he tokolahi ange ‘a e ngaahi kautaha hu‘i-faito‘ó ko e leleiange ia ki hono tau‘i ‘o e mahakí Covid-19. Ko e kautaha CEPI ‘oku nau faka-pa‘anga ‘a e ngaahi kautaha kumi faito‘ó ki he ngaahi mahaki pipihí hangē ko e Covid-19.
Tufaki ki he ngaahi fonua movetevete iikí
Ko e palopalema makehe ki he ngaahi fonua movetevete iikí ko e fiema‘u faka-mo‘uilelei ‘a hono tauhi ke ma‘ui‘ui mo malu ‘a e faito‘ó mei he tō-faikehekehe ‘o e ‘ātakaí ‘i natulá. Fakamatala ‘e CEO Hatchett ‘o e CEPI, ‘oku fiema‘u ke tauhi ‘a e BNT162b2 ‘i ha puha ‘aisi mokoteilo, pea ‘oku fiema‘u ke huhu tu‘o 2, fakavaha‘á uike 3.
“‘Oku faka-lotolahi pea faka-papau‘i,” ‘e he BNT162b2 ‘e vavé ni ha mateuteu ‘a e ngaahi kautaha kehe mo ‘enau faito‘o huhu-malu‘i, lau ia ‘a CEO Hatchett. Ko e ngaahi kautaha hu‘i-faito‘o eni kuo nau ‘osi kamata e sivi ‘o ‘enau faito‘o huhu-malu‘í:
• Pfizer and BioNTech report promising early results. Nov. 9
• New York-based Codagenix enters Phase 1. Nov. 7
• Turkey’s Erciyes University begins a Phase 1 trial. Nov. 7
• Canada’s Symvivo enters Phase 1. Nov. 2
Fakahoko ‘e he UNICEF mo e WHO
Kae kehe, ‘e ‘i ai ‘a e ngaahi fonua iiki movetevete kuo pau kenau fiema‘u ha faito‘o huhu ‘e lava ‘o tauhi ‘i he māfana mahení (room temperature). Pea fiema‘u foki ke huhu tu‘otaha pe, fakamatala ia ‘a CEO Hatchett. ‘I he ngaahi fonua ‘oku masiva puha ‘aisi mo e ‘uhilá ‘e faingata‘a hono tufaki mo hono tauhi ‘o e faito‘ó taimi fuoloa.
Ko e ngāue mamafá ‘e fai ‘e he WHO mo e UNICEF (va‘a ‘o e UN ‘i he malu‘i ‘o e fānau iikí) ki hono tufaki ‘o e faito‘o huhu-malu‘í. ‘Oku a‘u ki he 600-miliona ‘o faihake ki he 800-miliona ‘o e ngaahi me‘a-ngāue huhú (syringes) ‘oku nau faka-‘aonga‘i ‘i he ta‘ú ki he fānau iikí. Ka ‘e liunga-tou pe fā ‘a e fiema‘u ia ki he Covid-19.
‘Oku kau ‘a e palopalema tauhi faka-tolongá ‘o e faito‘o-huhú ‘i he ngaahi fonua movetevete iikí ko e faingatā‘ia ki hono tufakí. Ko e masiva faka-tolonga‘angá ‘o e faito‘ó ‘e toloi ai hono tufaki ki he ngaahi kolo mo e ngaahi ‘otumotu movetevete iikí.
[Liliu lea Tongá ‘a Mokofisi mei he fa‘utohi ‘a e kau faiongoongó ‘i he mītia faka-tu‘apule‘angá, ‘i he lea Pilitāniá. Ko e faiongoongo taukei na‘e ako‘i Liahona High School; Mesa Community College-Arizona (AA); BYU-Hawaii (BS); Universty of Phoenix-Arizona (MBA; doctoral candidate, DBA).]
